Whole Genome Sequencing (WGS) test now available through Foundation Medicine’s FlexOMx Lab™ to support biomarker discovery and drug development across cardiometabolic, immunologic and neurologic disease areas
Foundation Medicine, Inc., a global leader in precision medicine and genomic profiling, has announced the launch of its Whole Genome Sequencing (WGS) Germline test for research use. The new solution expands the company’s genomic testing portfolio and is now available through Foundation Medicine’s FlexOMx Lab™, enabling biopharmaceutical partners to advance translational research programs and retrospective clinical trials.
As precision medicine continues to reshape healthcare and medical innovation, comprehensive genomic insights are becoming critical for drug discovery and targeted therapy development. Foundation Medicine’s WGS Germline test provides extensive genome-wide coverage across both exonic and intronic regions, giving researchers deeper molecular insights needed to study complex and heterogeneous diseases.
Health Technology Insights: https://healthtechnologyinsights.com/genomic-ai-how-artificial-intelligence-is-powering-dna-based-nutrition-and-therapy/
The introduction of this advanced sequencing solution reflects the growing demand for high-quality germline genomic data across a wide range of disease areas beyond oncology. While the company has long been recognized for pioneering comprehensive genomic profiling in cancer care, the new WGS Germline test extends those capabilities into additional medical fields, including cardiometabolic, immunologic, and neurologic disorders.
Foundation Medicine has built a strong reputation for innovation in genomic diagnostics. The company recently achieved a significant milestone by reaching 100 approved companion diagnostic (CDx) indications, the highest number among comprehensive genomic profiling companies. This achievement underscores the company’s influence in advancing personalized medicine and precision-driven healthcare solutions worldwide.
According to Troy Schurr, Chief Commercial Officer at Foundation Medicine, the evolving biopharmaceutical landscape is driving greater demand for comprehensive genomic insights. As targeted therapies expand beyond traditional oncology and into broader therapeutic areas, researchers and drug developers increasingly require accurate germline data to understand disease biology, identify treatment pathways, and improve clinical outcomes.
The WGS Germline test offers biopharmaceutical partners the molecular foundation needed to move from generalized treatments toward highly personalized therapeutic approaches. By analyzing genome-wide genetic variation, the test helps researchers uncover hidden biological mechanisms behind chronic diseases and complex health conditions.
These insights can be used to evaluate polygenic risk scores that predict disease susceptibility, as well as pharmacogenomic response markers that help identify potential adverse drug reactions before treatment begins. Such capabilities support the development of safer and more effective therapies tailored to the genetic profiles of individual patients.
Health Technology Insights: https://healthtechnologyinsights.com/healthtechtop-voice-interview-with-wendy-winkler-chief-scientific-officer-at-droplet-biosciences/
In addition to supporting drug discovery, the WGS Germline test enables researchers to decode disease progression patterns and uncover novel biological targets. By translating genomic insights into actionable research data, Foundation Medicine aims to help pharmaceutical companies design next-generation therapies and accelerate clinical trial success.
The test is part of Foundation Medicine’s broader portfolio of genomic testing and multi-omic research solutions available through its FlexOMx Lab platform. These services are designed to support biopharmaceutical partners at every stage of therapeutic development, from early discovery research to later-stage clinical validation.
By providing integrated genomic insights, Foundation Medicine helps drug developers reduce program risk, improve biomarker discovery, and streamline the transition between clinical development phases.
With the launch of the Whole Genome Sequencing Germline test, Foundation Medicine continues expanding the role of genomic intelligence in healthcare research. The new offering reinforces the company’s commitment to advancing precision medicine and enabling a future where personalized therapies are guided by a deep genetic understanding of disease biology.
Health Technology Insights: https://healthtechnologyinsights.com/the-new-healthtech-stack-ai-trials-and-smart-capital/
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
